Featured
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised $32 million in Series A round of financing.
CARsgen and Moderna to evaluate CT041 in combo with an mRNA cancer vaccine
US mRNA specialist Moderna (Nasdaq: MRNA) saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ (2171: HK) investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.
CARsgen collaborated with Moderna to evaluate CAR-T in combination with mRNA cancer vaccines
CARsgen announced that it and Moderna have launched a collaboration agreement to study the combined therapeutic effects of CARsgen Pharmaceutical's Claudin 21.18 CAR-T product candidate (CT2) with Moderna's investigational Claudin 041.18 mRNA cancer vaccine.
妙顺生物完成超亿元A轮融资，凯乘资本担任独家财务顾问
近日，妙顺（上海）生物科技有限公司（以下简称：妙顺生物）宣布完成超亿元A轮融资，本轮融资由中科海创领投，毅达资本、高瓴创投(GL Ventures)、泰坦科技（688133.SH）、同毓基金跟投，凯乘资本担任独家财务顾问。本轮融资获得了国家队基金、著名投资机构以及上市公司的认可和支持，募集资金将主要用于加速一系列原代细胞及配套试剂耗材产品的开发，以及进一步加强企业海内外商业化拓展能力。
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints in adult patients with primary immune thrombocytopenia.
Dizal’s Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations
Dizal today announced that sunvozertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations, whose disease has progressed on or after platinum-based chemotherapy.
magAssist’s NyokAssist™️ granted Designation by the FDA as a Breakthrough Device
Recently, magAssist's NyokAssist™ Interventional Ventricular Assist Device (hereinafter referred to as NyokAssist™), has been granted designation as a breakthrough device by the U.S. Food and Drug Administration (FDA) in Breakthrough Device Program.
Six-month extension of the U.S.-China Science and Technology Cooperation Agreement: What different factions in the United States think
This week, the Agreement Between the United States and China on Cooperation in Science and Technology expired. The Biden administration, under strong pressure from both the pro and the opposite, decided to take a stopgap measure and extend the agreement for six months.
The China contagion that never was
Markets aren’t worried about China contagion – and you shouldn’t be, either.
Will NEUCA be taken over by the Chinese?
According to unofficial information from the authors, talks are underway about the acquisition of a controlling stake in Neuci by a consortium of Chinese companies, including Sinopharma.
